Impact of topiramate migraine prophylaxis on workplace productivity: Results from two US randomized, double-blind, placebo-controlled, multicenter trials

Journal of Occupational and Environmental Medicine

Volumn 49, Issue 3, 2007, Pages 252-257

  Lofland, Jennifer H ^a,d   Gagne, Joshua J ^a,b   Pizzi, Laura T ^a   Rupnow, Marcia ^b   Silberstein, Stephen D ^c  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^c THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

^d THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; TOPIRAMATE;

ABSENTEEISM; ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; JOB PERFORMANCE; MAJOR CLINICAL STUDY; MALE; MIGRAINE; MULTICENTER STUDY; PRODUCTIVITY; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; STATISTICAL SIGNIFICANCE; UNITED STATES; WORK ENVIRONMENT; WORKPLACE;

ABSENTEEISM; ADOLESCENT; ADULT; DOUBLE-BLIND METHOD; EFFICIENCY; FEMALE; FRUCTOSE; HUMANS; MALE; MIDDLE AGED; MIGRAINE DISORDERS; NEUROPROTECTIVE AGENTS; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME;

EID: 33947109809     PISSN: 10762752     EISSN: None     Source Type: Journal    
DOI: 10.1097/JOM.0b013e3180322134     Document Type: Article

References (51)

1. The Henry J Kaiser Family Foundation. Employee health benefits 2005 annual survey. 2005. Available at http://www.kff.org/insurance/7315.cfm.
2. McKinsey and Company. Will health benefit costs eclipse profits? The McKinsey Quarterly Chart Focus Newsletter. September 2004. Available at http://www.mckinseyquarterly.com/newsletter/chartfocus/2004_09.htm.
3. Aldana SG, Greenlaw RL, Diehl HA, Salberg A, Merrill RM, Ohmine S. The effects of a worksite chronic disease prevention program. J Occup Environ Med. 2005;47:558-564.
4. Aldana SG, Greenlaw R, Diehl HA, Englert H, Jackson R. Impact of the coronary health improvement project (CHIP) on several employee populations. J Occup Environ Med. 2002;44:831-839.
5. Warshaw LJ, Burton WN. Cutting the costs of migraine: role of the employee health unit. J Occup Environ Med. 1998;40:943-953.
6. Warshaw LJ, Burton WN, Schneider WJ. Role of the workplace in migraine disease management. Dis Manag Health Outcomes. 2001;99-115.
7. Gaugris S, Sazonov-Kocevar V, Thomas M. Burden of concomitant allergic rhinitis in adults with asthma. J Asthma. 2006;43:1-7.
8. Cisternas MG, Blanc PD, Yen IH, et al. A comprehensive study of the direct and indirect costs of adult asthma. J Allergy Clin Immunol. 2003;111:1212-1218.
9. Lo Sasso AT, Rost K, Beck A. Modeling the impact of enhanced depression treatment on workplace functioning and costs: a cost-benefit approach. Med Care. 2006;44:352-358.
10. Tunceli K, Bradley CJ, Nerenz D, et al. The impact of diabetes on employment and work productivity. Diabetes Care. 2005;28:2662-2667.
11. Vijan S, Hayward RA, Langa KM. The impact of diabetes on workforce participation: results from a national household sample. Health Serv Res. 2004;39:1653-1669.
12. Kwong WJ, Taylor FR, Adelman JU. The effect of early intervention with sumatriptan tablets on migraine-associated productivity loss. J Occup Environ Med. 2005;47:1167-1173.
13. Bussone G, D'Amico D, McCarroll KA, Gerth W, Lines CR. Restoring migraine sufferers' ability to function normally: a comparison of rizatriptan and other triptans in randomized trials. Eur Neurol. 2002;48:172-177.
14. Dasbach EJ, Carides GW, Gerth WC, et al. Work and productivity loss in the rizatriptan multiple attack study. Cephalalgia. 2000;20:830-834.
15. McCormack PL, Foster RH. Rizatriptan: a pharmacoeconomic review of its use in the acute treatment of migraine. Pharmacoeconomics. 2005;23:1283-1298.
16. Lipton RB, Scher AI, Kolodner K, et al. Migraine in the United States: epidemiology and patterns of health care use. Neurology. 2002;58:885-894.
17. Adeney KL, Flores JL, Perez JC, et al. Prevalence and correlates of migraine among women attending a prenatal care clinic in Lima, Peru. Cephalalgia. 2006;26:1089-1096.
18. Sedighi B, Ghaderi-Sohi S, Emami S. Evaluation of self-medication prevalence, diagnosis and prescription in migraine in Kerman, Iran. Saudi Med J. 2006;27:377-380.
19. Aegidius K, Zwart JA, Hagen K, et al. Oral contraceptives and increased headache prevalence: the Head-HUNT Study. Neurology. 2006;66:349-353.
20. Lanteri-Minet M, Valade D, Geraud G, et al. Migraine and probable migraine - results of FRAMIG 3, a French nationwide survey carried out according to the 2004 IHS classification. Cephalalgia. 2005;25:1146-1158.
21. Morillo LE, Alarcon F, Aranaga N, et al. Prevalence of migraine in Latin America. Headache. 2005;45:106-117.
22. Celik Y, Ekuklu G, Tokuc B, Utku U. Migraine prevalence and some related factors in Turkey. Headache. 2005;45:32-36.
23. Hu XH, Markson LE, Lipton RB, Stewart WF, Berger ML. Burden of migraine in the United States: disability and economic costs. Arch Intern Med. 1999;159:813-818.
24. Osterhaus JT, Gutterman DL, Plachetka JR. Healthcare resource and lost labour costs of migraine headache in the US. Pharmacoeconomics. 1992;2:67-76.
25. Solomon GD, Price KL. Burden of migraine. A review of its socioeconomic impact. Pharmacoeconomics. 1997;11 Suppl 1:1-10.
26. Solomon GD, Litaker DG. The impact of drug therapy on quality of life in headache and migraine. Pharmacoeconomics. 1997;11:334-342.
27. Edmeads J, Findlay H, Tugwell P, et al. Impact of migraine and tension-type headache on life-style, consulting behaviour, and medication use: a Canadian population survey. Can J Neurol Sci. 1993;20:131-137.
28. Michel P, Dartigues JF, Duru G, et al. Incremental absenteeism due to headaches in migraine: results from the Mig-Access French national cohort. Cephalalgia. 1999;19:503-510.
29. Osterhaus JT, Townsend RJ, Gandek B, Ware JE Jr. Measuring the functional status and well-being of patients with migraine headache. Headache. 1994;34:337-343.
30. Mushet GR, Miller D, Clements B, Pait G, Gutterman DL. Impact of sumatriptan on workplace productivity, nonwork activities, and health-related quality of life among hospital employees with migraine. Headache. 1996;36:137-143.
31. Miller DW, Martin BC, Loo CM. Sumatriptan and lost productivity time: a time series analysis of diary data. Clin Ther. 1996;18:1263-1275.
32. Greiner DL, Addy SN. Sumatriptan use in a large group-model health maintenance organization. Am J Health Syst Pharm. 1996;53:633-638.
33. Cady RC, Ryan R, Jhingran P, O'Quinn S, Pait DG. Sumatriptan injection reduces productivity loss during a migraine attack: results of a double-blind, placebocontrolled trial. Arch Intern Med. 1998;158:1013-1018.
34. Lofland JH, Johnson NE, Batenhorst AS, Nash DB. Changes in resource use and outcomes for patients with migraine treated with sumatriptan: a managed care perspective. Arch Intern Med. 1999;159:857-863. Erratum in: Arch Intern Med. 1999;159:2228.
35. Koopman C, Pelletier KR, Murray JF, et al. Stanford presenteeism scale: health status and employee productivity. J Occup Environ Med. 2002;44:14-20.
36. Diamond M, Dahlof C, Papadopoulos G, et al. Topiramate improves health-related quality of life when used to prevent migraine. Headache. 2005;45:1023-1030.
37. D'Amico D, Solari A, Usai S, et al. Improvement in quality of life and activity limitations in migraine patients after prophylaxis. A prospective longitudinal multicentre study. Cephalalgia. 2006;26:691-696.
38. Tronvik E, Stovner LJ, Helde G, Sand T, Bovim G. Prophylactic treatment of migraine with an angiotensin II receptor blocker: a randomized controlled trial. JAMA. 2003;289:65-69.
39. Schrader H, Stovner LJ, Helde G, Sand T, Bovim G. Prophylactic treatment of migraine with angiotensin converting enzyme inhibitor (lisinopril): randomised, placebo controlled, crossover study. BMJ. 2001;322:19-22.
40. Silberstein SD, Neto W, Schmitt J, Jacobs D; MIGR-001 Study Group. Topiramate in migraine prevention: results of a large controlled trial. Arch Neurol. 2004;61:490-495.
41. Brandes JL, Saper JR, Diamond M, et al. Topiramate for migraine prevention: a randomized controlled trial. JAMA. 2004;291:965-973.
42. Liljas B. How to calculate indirect costs in economic evaluations. Pharmacoeconomics. 1998;13:1-7.
43. Stewart WF, Ricci JA, Chee E, Hahn SR, Morganstein D. Cost of lost productive work time among US workers with depression. JAMA. 2003;289:3135-3144. Erratum in: JAMA. 2003;290:2218.
44. Stewart WF, Ricci JA, Chee E, Morganstein D. Lost productive work time costs from health conditions in the United States: results from the American Productivity Audit. J Occup Environ Med. 2003;45:1234-1246.
45. Ricci JA, Stewart WF, Chee E, Leotta C, Foley K, Hochberg MC. Pain exacerbation as a major source of lost productive time in US workers with arthritis. Arthritis Rheum. 2005;53:673-681.
46. Diener HC, Tfelt-Hansen P, Dahlof C, et al. Topiramate in migraine prophylaxis - results from a placebo-controlled trial with propranolol as an active control. J Neurol. 2004;251:943-950.
47. Daly MC, Bound J. Worker adaptation and employer accommodation following the onset of health impairment. J Gerontol B Psychol Sci Soc Sci. 1996;51:S53-S60.
48. Pizzi LT, Smith KD, Gagne JJ. Pills and productivity: collecting and using data from clinical trials. Read at the Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Philadelphia, PA, 2006.
49. Vicente-Herrero T, Burke TA, Lainez MJ. The impact of a worksite migraine intervention program on work productivity, productivity costs, and non-workplace impairment among Spanish postal service employees from an employer perspective. Curr Med Res Opin. 2004;20:1805-1814.
50. Campinha-Bacote DL, Kendle JB, Jones C, et al. Impact of a migraine management program on improving health outcomes. Dis Manag. 2005;8:382-391.
51. Blumenfeld AM. An integrated management program for migraine: The Kaiser experience. Manag Care Interface. 2004;17 Suppl D:18-30.